Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody aims to tame rare bleeding disorder

NCT ID NCT07623525

Disease control Sponsor: Diagonal Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 7 times

Summary

This early-phase trial tests an experimental antibody called DIAG723 in 93 adults with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds. The study will check if the drug is safe and how the body processes it, with some participants receiving a placebo. It also includes a small group of HHT patients who have a related lung condition called pulmonary arterial hypertension.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DIAG723, an experimental antibody that targets two proteins to help repair blood vessels
What this could lead to
If successful, this could point toward a new treatment to reduce bleeding and other complications in people with HHT.
What could go wrong
This is a very early first-in-human study with only 93 participants, so safety and effectiveness are not yet known. The drug may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 93 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients ≥18 years with a clinical or genetic diagnosis of HHT * Adequate hepatic and renal function * Part B: Epistaxis and anemia or transfusion/iron history * Part C: HHT with documented pre-capillary pulmonary arterial hypertension Exclusion Criteria: * Active or recent systemic infection * Recent thromboembolic events * Use of anti-angiogenic drugs within 6 weeks * Pregnancy or lactation * Recent participation in another investigational study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hereditary hemorrhagic telangiectasia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hereditary hemorrhagic telangiectasia pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hereditary hemorrhagic telangiectasia Pulmonary arterial hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    10 sites in 3 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Diagonal Investigational Site

    NOT_YET_RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Diagonal Investigational Site

    RECRUITING

    Randwick, New South Wales, 2031, Australia

  • Diagonal Investigational Site

    NOT_YET_RECRUITING

    Herston, Queensland, 4029, Australia

  • Diagonal Investigational Site

    WITHDRAWN

    Herston, Queensland, 4029, Australia

  • Diagonal Investigational Site

    RECRUITING

    East Melbourne, Victoria, 3002, Australia

  • Diagonal Investigational Site

    NOT_YET_RECRUITING

    Parkville, Victoria, 3052, Australia

  • Diagonal Investigational Site

    NOT_YET_RECRUITING

    West Perth, Western Australia, 6005, Australia

  • Diagonal Investigational Site

    NOT_YET_RECRUITING

    Toronto, Ontario, M5B1W8, Canada

  • Diagonal Investigational Site

    NOT_YET_RECRUITING

    Toronto, Ontario, M9L 3A2, Canada

  • Diagonal Investigational Site

    NOT_YET_RECRUITING

    Laval, Quebec, H7V 4B3, Canada

  • Diagonal Investigational Site

    RECRUITING

    Grafton, Auckland, 1010, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.